Home › Compugen Presents Results For CGEN-15029 Immuno-Oncology Program
 

Keywords :   


Compugen Presents Results For CGEN-15029 Immuno-Oncology Program

2016-03-01 01:32:56| drugdiscoveryonline News Articles

In an oral presentation today at the New York Academy of Sciences' Emerging Approaches to Cancer Immunotherapy conference, John Hunter, Ph.D., Site Head and Vice President of Antibody R&D at Compugen USA, Inc., a wholly owned subsidiary of Compugen Ltd. (NASDAQ: CGEN), presented results for CGEN-15029, the lead internal program in the Company's immuno-oncology therapeutics pipeline.

Tags: results program presents presents results

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
03.07Hurricane Beryl Graphics
03.07Hurricane Beryl Public Advisory Number 18A
03.07Summary for Hurricane Beryl (AT2/AL022024)
03.07Eastern North Pacific Tropical Weather Outlook
03.07Atlantic Tropical Weather Outlook
03.07Benefits of benchmarking in the pork industry
03.07Hurricane Beryl Graphics
03.07Hurricane Beryl Forecast Discussion Number 18
More »